I really don't see the marijuana aspect of the company as being an important part right now. Most important are the two studies having to do with ascites and inoperable pancreatic cancer. Results of which are near term.
A third important part is the type 1 live cell diabetes. This study is longer term and may take a while.
Kind of disappointed with the cash burn and dilution aspect. Looks like another stock that may have to reverse split later on. A reverse split may not be a bad thing if these studies are successful. An example is Advaxis (ADXS).
I will wait on this one to see where things go.
Been burned too many times with reverse splits such as CTSO and ADXS. Good companies.... I just got in too soon with ADXS. CTSO I had no position but that is another good company doing well after a reverse split. Will wait for PMCB.
I agree... When they give the permission to study... It could be very exciting.. We all know that it was wrong of NIXON to put MJ on the list. The herb was studied by the Israeli's back in the 80's and 90's.. And approved for use in their country. This war on drugs has cost countless dollars and lives ruined.
When our daughter passed from Leukemia, they gave us a case (24) vials of morphine for the pain.. It had little to no effect. I would have been happy to have something for her that was natural and could have really taken the edge off her pain.
Well we just recently made our first payment for licensing rights to use cannabanoids with Cell in a Box technology and we are currently working on a new cell line to be used.
"Progress is ongoing at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as a treatment for deadly cancers - such as brain and pancreatic cancer."
Amazing how many uses for Cell in a Box that we are working on...
News 
Market Data 
Discover 
